Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fipronil + cyphenothrin** is a topical combination ectoparasiticide approved for use in dogs to control and treat infestations by fleas, ticks, and chewing lice[1][5][6]. The main brand name is Parastar Plus. It may also be effective as a treatment for sarcoptic mange and is sometimes used off-label for other ectoparasitic conditions in dogs[1]. - **Mechanism of action:** - Fipronil acts primarily as an insecticide by blocking GABA-gated chloride channels in nerve cells, resulting in hyperexcitation and death of the target parasites[5][6]. - Cyphenothrin is a synthetic pyrethroid that targets voltage-sensitive sodium channels, holding them open longer and causing persistent neuronal excitation leading to paralysis and death of insects[5][6]. - This combination exhibits broad-spectrum activity, providing rapid (effect within minutes) and persistent protection (up to 4 weeks) against targeted ectoparasites. - The product demonstrates high selectivity for insect targets over mammals, and safety data show minimal adverse effects in dogs when used according to instructions[5][6]. - Developed and manufactured by Merial (now part of Boehringer Ingelheim)[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fipronil + cyphenothrin.